Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Rigel Pharmaceuticals stock (RIGL)

Buy Rigel Pharmaceuticals stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Rigel Pharmaceuticals is a biotechnology business based in the US. Rigel Pharmaceuticals shares (RIGL) are listed on the NASDAQ and all prices are listed in US Dollars. Rigel Pharmaceuticals employs 147 staff and has a trailing 12-month revenue of around $119.2 million.

Our top picks for where to buy Rigel Pharmaceuticals stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Best for beginners

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for cash sweep

Go to site
Advanced charts and trading tools
  • Trade stocks, ETFs and equity options without commission and $0 option contract fees
  • Earn up to 8.1% APY on your uninvested cash
  • Get a 1.5% match in cash on transferred assets up to $300 or up to 15 free fractional shares worth between $2 and $2,000

How to buy Rigel Pharmaceuticals stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – RIGL. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Rigel Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Finder Score: 4.4 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
Stocks, Options, Mutual funds, ETFs, Alternatives
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
Finder Score: 4.3 / 5: ★★★★★
Stocks, Options, ETFs
Up to 8.10%
Choose a 1.5% match or up to 15 free fractional shares
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Finder Score: 4.2 / 5: ★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Rigel Pharmaceuticals stock price (NASDAQ: RIGL)

Use our graph to track the performance of RIGL stocks over time.

Rigel Pharmaceuticals shares at a glance

Information last updated 2024-07-14.
Latest market close$9.98
52-week range$7.12 - $17.30
50-day moving average $9.52
200-day moving average $11.23
Wall St. target price$42.83
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.10

Is it a good time to buy Rigel Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Rigel Pharmaceuticals price performance over time

Historical closes compared with the close of $9.98 from 2024-07-12

1 week (2024-07-09) 22.60%
1 month (2024-06-14) 947.22%
3 months (2024-04-16) 775.44%
6 months (2024-01-16) 633.82%
1 year (2023-07-14) 692.06%
2 years (2022-07-15) 661.83%
3 years (2021-07-16) 145.81%
5 years (2019-07-16) 299.20%

Rigel Pharmaceuticals financials

Revenue TTM $119.2 million
Gross profit TTM $53.7 million
Return on assets TTM -7.91%
Return on equity TTM -699.05%
Profit margin -16.61%
Book value $-1.81
Market Capitalization $175.2 million

TTM: trailing 12 months

Rigel Pharmaceuticals share dividends

We're not expecting Rigel Pharmaceuticals to pay a dividend over the next 12 months.

Have Rigel Pharmaceuticals's shares ever split?

Rigel Pharmaceuticals's shares were split on a 1:10 basis on 26 June 2024. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Rigel Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Rigel Pharmaceuticals shares which in turn could have impacted Rigel Pharmaceuticals's share price.

Rigel Pharmaceuticals share price volatility

Over the last 12 months, Rigel Pharmaceuticals's shares have ranged in value from as little as $7.12 up to $17.3. A popular way to gauge a stock's volatility is its "beta".

RIGL.US volatility(beta: 0.96)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rigel Pharmaceuticals's is 0.959. This would suggest that Rigel Pharmaceuticals's shares are less volatile than average (for this exchange).

Rigel Pharmaceuticals overview

Rigel Pharmaceuticals, Inc. , a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Frequently asked questions

What percentage of Rigel Pharmaceuticals is owned by insiders or institutions?
Currently 2.189% of Rigel Pharmaceuticals shares are held by insiders and 63.833% by institutions.
How many people work for Rigel Pharmaceuticals?
Latest data suggests 147 work at Rigel Pharmaceuticals.
When does the fiscal year end for Rigel Pharmaceuticals?
Rigel Pharmaceuticals's fiscal year ends in December.
Where is Rigel Pharmaceuticals based?
Rigel Pharmaceuticals's address is: 611 Gateway Blvd, South San Francisco, CA, United States, 94080
What is Rigel Pharmaceuticals's ISIN number?
Rigel Pharmaceuticals's international securities identification number is: US7665596034
What is Rigel Pharmaceuticals's CUSIP number?
Rigel Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 766559108

More guides on Finder

Ask a Question provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site